Epilepsy is one of the most common neurologic conditions affecting women. Care for women with epilepsy requires expertise not only in seizure treatment, but also an understanding of the unique challenges presented in the treatment of women with epilepsy. Epilepsy and antiseizure medications (ASMs) interact with aspects of health care specific to women, including sexual and reproductive health, menstrual cycle, contraception and family planning, teratogenesis, and pregnancy. Knowledge of these issues allows providers to identify and anticipate circumstances in which epilepsy and its treatment overlap with topics of importance to women.
Reproductive Hormones and Epilepsy
The primary female reproductive hormones, estrogen and progesterone have proconvulsant and anticonvulsive effects, respectively.1 These properties are suspected to be involved in the clustering of seizures during various phases of the menstrual cycle, termed catamenial epilepsy and attributed to neuro-steroid effects of these hormones. Catamenial epilepsy is estimated to affect as many as a third of women with epilepsy.2,3
Several therapeutic efforts have been made to lessen catamenial seizures through nonhormonal and hormonal methods. Small studies investigating acetazolamide and clobazam reported improvement in catamenial seizure exacerbations.4-6 Menstrual cycle suppression with medroxyprogesterone acetate is associated with reduced seizure frequency, most likely because of hormone cycling inhibition.7 Using a similar rationale, uninterrupted combined hormone contraceptive (CHC)use and transient increases in daily ASM doses (25%-50% during the highest risk portion of the cycle) are suggested for catamenial seizure management.8 A double-blind trial assessing exogenous progesterone treatment did not affect catamenial seizure frequency. A subset of women in this trial who had a threefold or more seizure increase during the perimenstrual phase of their cycle, however, did have seizure reduction.9
More recently, clinical trials of a progesterone metabolite with neurosteroid effects, allopregnanolone, and its synthetic analog, ganaxolone, have suggested a unique strategy for treatment of women with epilepsy. This strategy includes neurosteroid replacement therapy for women whose seizures are exacerbated by falling progesterone with subsequent endogenous allopregnanolone levels during their menstrual cycle.10
Reproductive and Sexual Concerns
Polycystic ovarian syndrome (PCOS) is associated with epilepsy treatment and can affect fertility. Studies note an association with valproate use,11-13 known to increase ovarian androgen synthesis.14 In a prospective clinical trial, women with epilepsy who initiated valproate treatment had higher serum testosterone levels, increased development of obesity, and irregular menses compared with women who initiated treatment with lamotrigine. In the same study, women who transitioned from valproate to lamotrigine had significant reductions in serum testosterone and body mass index (BMI).15
Epilepsy diagnosis and treatment do not appear to affect fertility. In the absence of an underlying fertility problem, such as PCOS, women with epilepsy do not appear to have differences in the likelihood of conceiving, time to conception, and live birth rate compared with women without epilepsy.16
Reduced sexual desire, problems with orgasm, vaginal dryness, dyspareunia, and overall dissatisfaction with sex life, occur at significantly higher rates in women with epilepsy vs those without epilepsy.17,18 Sexual dysfunction is independent of seizure frequency and enzyme-inducing ASM treatment.19 In contrast to other ASMs, lamotrigine is associated with improved sexual desire, pleasure, and orgasm.20
Contraception and Family Planning
Approximately 80% of women with epilepsy report having at least 1 unintended pregnancy, and 54.6% of the most recent pregnancies in women with epilepsy were unintended, compared with 47.6% of pregnancies in women without epilepsy.21,22 Because exposure to certain ASMs increases the risk of birth defects, counseling regarding folic acid supplementation, contraception, and pregnancy is considered a quality measure for women with epilepsy of reproductive age.23 Women taking valproic acid or carbamazepine should take 4 mg/day of folic acid; others should take a standard dose of 0.4 to 0.8 mg/day.
Effective contraception potentially decreases the risk of unintended pregnancy, and highly effective contraception (eg, intrauterine devices [IUDs], contraceptive implants, tubal ligation, or partner vasectomy) has less than a 1% failure rate in the first year of use.24 These methods also do not have any drug interactions with enzyme-inducing ASMs. Highly effective contraception, however, is often underutilized in women with epilepsy. In the 2017 Epilepsy Birth Control Registry (EBCR) survey data, approximately 38% of women with epilepsy at risk of pregnancy were using highly effective contraception (hormonal IUD, 22.0%; copper IUD, 8.6%; implant, 4.8%; and male or female permanent contraception, 2.2%).25
Safety of specific contraceptive methods for women with epilepsy is dependent primarily on the ASM regimen or other comorbidities, as outlined in the Centers for Disease Control Medical Eligibility Criteria for Contraceptive Use (Table 1).26 Steroid hormones are metabolized by the cytochrome P450 enzymes, and use of enzyme-inducing ASMs can decrease effectiveness of some systemic hormonal contraception, including pills, patches, or the vaginal ring. Although weak enzyme-inducing ASMs theoretically also decrease steroid hormones, the clinical effect in the context of hormonal contraception is unclear. In contrast, estrogen-containing methods can increase lamotrigine metabolism through glucuronidation. Despite these important drug interactions, several studies show that many women are not adequately counseled about possible drug interactions between ASMs and contraception. In one academic practice, only 26% of women with epilepsy who were taking a potentially teratogenic ASM had a documented contraceptive method. Of those, approximately half were using a contraceptive method with potential drug interactions with their ASM regimen.27 In another study, 35% of women with epilepsy received contraceptive counseling; those who were counseled about IUDs by their epileptologist were more likely to obtain an IUD, indicating the important role that neurologists play in contraceptive counseling.28
Major congenital malformations (MCMs) are associated with intrauterine ASM exposure (Figure). Neural tube defects occur within the first 3 to 4 weeks of gestation, before many women know they are pregnant.29 Proactive counseling about ASM risks during pregnancy is therefore vital for women with epilepsy with childbearing potential. These risks must be discussed before conception to allow for careful planning to minimize risks to both mother and fetus.
Folate supplementation prevents neural tube defects and is recommended for women with epilepsy.30,31 Although studies have not shown that folate supplementation reduces ASM-associated MCMs, there is evidence that folate supplementation is associated with less severe effects of ASMs on an exposed child’s IQ, autistic traits, and verbal abilities.32-38
Increasing awareness of ASM-associated MCMs has influenced changes in ASM prescribing.39 Use of valproate is associated with a significantly higher rate of MCMs compared with other ASMs, and lamotrigine, levetiracetam, and oxcarbazepine have been associated with lower rates.40-42 Further studies have also identified valproate-associated cognitive teratogenesis including intellectual disabilities, autism spectrum disorder, and ADHD.36,43,44 The Food and Drug Administration (FDA) and European Medical Agency (EMA) have updated prescribing information, recommending against the use of valproate in women of reproductive potential unless other appropriate therapies have proven ineffective.45,46
Efforts to influence prescription patterns of ASMs to women with epilepsy appear to be reducing MCMs. Recent analysis of the International Registry of Antiepileptic Drugs and Pregnancy (EURAP) from 2000 to 2013 showed significantly fewer valproate and carbamazepine prescriptions and more lamotrigine and levetiracetam prescriptions. During the same period, a 27% reduction in MCMs was seen.47 Valproate prescriptions for nonepileptic conditions to women of reproductive age also appears to be decreasing, although challenges remain for access to ASMs with lower rates of teratogenesis by women with epilepsy in developing countries.48-50
Two-thirds of women with epilepsy remain seizure free during pregnancy, with better seizure control observed among those with generalized epilepsy syndromes and those who are seizure free for at least 9 months before pregnancy.31,51 Fewer than 16% of women experience worsening seizure frequency from first to second or third trimester, which is attributed to physiologic changes in serum ASM concentrations.51 Pregnancy-related changes (eg, increased volume of distribution and renal clearance, reduced serum albumin, and estrogen-induced hepatic induction and glucuronidation) affect ASM pharmacokinetics.52-54 Although certain ASMs, (eg, lamotrigine and levetiracetam) have reduced risk of teratogenesis, these ASMs can also undergo profound serum concentration reduction during pregnancy, the degree of which is variable among individuals.55 The increased metabolism can raise seizure risk, with highest risk increase associated with lamotrigine.51 Serum ASM concentration monitoring has been suggested as a management strategy, although it is yet to be determined whether monitoring improves seizure control.56,57
A tenfold increased risk of maternal mortality is reported in women with epilepsy, primarily attributed to sudden unexpected death in epilepsy (SUDEP) during pregnancy or postpartum.58 The majority of cases are associated with lamotrigine and may be directly related to pregnancy-induced serum concentration reduction. For women who have increased seizures during pregnancy, a higher frequency of bilateral tonic-clonic seizures is associated with cognitive teratogenesis.59 Deterioration in seizure control occurs in women with a 35% or greater reduction in serum ASM concentrations, suggesting that a more significant decline in ASM concentrations may warrant more frequent monitoring.55,60 As pregnancy-related changes resolve within weeks after delivery, ASM concentrations may change, making it essential to have a plan for tapering ASMs back to prepregnancy dose after delivery.55 Failure to do so can result in serious toxicity. These observations highlight not only the need for regular monitoring of serum ASM concentrations before conception, during pregnancy, and throughout the postpartum period, but also the importance of balancing maternal and fetal risks in ASM selection.
Breastfeeding confers multiple benefits on infants and their mothers. Infants who are breastfed receive protection from respiratory tract infections, otitis media, gastrointestinal infections, obesity, and diabetes. Women who report breastfeeding also experience a decreased risk of diabetes, hypertension, and breast and ovarian cancer. The American Academy of Pediatrics recommends exclusive breastfeeding for 6 months and continuation of breastfeeding for 1 year or longer with the addition of complementary foods.61 Despite these recommendations, data from the Centers for Disease Control Pregnancy Risk Assessment Monitoring System indicates that only 69.1% of women with epilepsy breastfeed their infants for any length of time compared with 84.6% of women without epilepsy.22
Although 2 prospective cohort studies have shown there is no harm to infants breastfed by women with epilepsy, new mothers with epilepsy may receive conflicting advice because of concern for infant exposure to ASMs through breast milk. In a population-based prospective study, standardized validated scales were used to rate children’s development and behavior at 6, 18, and 36 months of age. Compared with infants of women without epilepsy, children of women with epilepsy taking ASMs had impaired fine motor skills at age 6 months, but breastfeeding seemed to mitigate adverse developmental outcomes in children of women with epilepsy who were taking ASMs.62 In another prospective observational study of children of women with epilepsy who took ASMs, at age 6 years, those who were breastfed had adjusted IQ scores that were 4 points higher than those who were not breastfed.63
Several factors determine an infant’s exposure to an ASM in breast milk, including maternal plasma concentrations, timing of breastfeeding, amount of breast milk ingested, and the child’s ability to metabolize medications (Table 2).62,64 The Drugs and Lactation Database is a useful guide to the safety of a drug in breastfeeding dyads.65 The overall benefits of breastfeeding for mothers and infants may outweigh potential risks; individual discussions with patients about their breastfeeding goals in the context of their ASM regimen are important.
Menopause and Bone Health
Menopause is associated with seizure worsening for 40% of women with epilepsy, although 27% report improvement, which may indicate hormonal influence on seizures.66 Women with catamenial epilepsy may have a higher rate of seizures during the perimenopause transition, followed by a reduction in seizures after menopause. Estrogen hormone replacement therapy is associated with increased seizure frequency and is not recommended for women with epilepsy.67,68
Menopausal women have an elevated risk for osteopenia and osteoporosis, which is likely further increased in women with epilepsy. Reduced bone density has been observed with both newer and older generation ASMs.69 Women of reproductive age may acquire additional increased risk of bone density loss with use of medroxyprogesterone acetate.70 Vitamin D supplementation may improve bone density in women with epilepsy and has been shown to improve markers of bone density loss (serum calcium, alkaline phosphatase, parathyroid hormone).71 The current recommendation is to take at least 1,200 mg/day of calcium, 800 IU/day of vitamin D, and monitor serum 25-hydroxyvitamin D.
1. Harden CL, Pennell PB.Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12(1):72-83.
2. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol. 2004;56(3):431-434.
3. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38(10):1082-1088.
4. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia. 2001;42(6):746-749.
5. Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet. 1982;2(8289):71-73.
6. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry. 1984;47(12):1279-1282.
7. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology. 1984;34(9):1255-1258.
8. Navis A, Harden C. A treatment approach to Catamenial epilepsy. Curr Treat Options Neurol. 2016;18(7):30.
9. Herzog AG, Fowler KM, Smithson SD, et al. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology. 2012;78(24):1959-1966.
10. Reddy DS, Estes WA. Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci. 2016;37(7):543-561.
11. Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97(1-2):73-82.
12. Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008;64(2):200-211.
13. Zhou JQ, Zhou LM, Chen LJ, et al. Polycystic ovary syndrome in patients with epilepsy: a study in 102 Chinese women. Seizure. 2012;21(9):729-733.
14. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology. 2004;145(2):799-808.
15. Sidhu HS, Srinivasa R, Sadhotra A. Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either valproate or lamotrigine monotherapy: a prospective study. Epilepsy Res. 2018;139:20-27.
16. Pennell PB, French JA, Harden CL, et al. Fertility and birth outcomes in women with epilepsy seeking pregnancy. JAMA Neurol. 2018;75(8):962-969.
17. Harden CL. Sexual dysfunction in women with epilepsy. Seizure. 2008;17(2):131-135.
18. Henning OJ, Nakken KO, Træen B, Mowinckel P, Lossius M. Sexual problems in people with refractory epilepsy. Epilepsy Behav. 2016;61:174-179.
19. Henning O, Johannessen Landmark C, Traeen B, et al. Sexual function in people with epilepsy: similarities and differences with the general population. Epilepsia. Published Online: Aug 13, 2019 (. doi: 10.1111/epi.16311).
20. Gil-Nagel A, López-Muñoz F, Serratosa JM, Moncada I, García-García P, Alamo C. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure. 2006;15(3):142-149.
21. Herzog AG, Mandle HB, Cahill KE, Fowler KM, Hauser WA. Predictors of unintended pregnancy in women with epilepsy. Neurology. 2017;88(8):728-733.
22. Johnson EL, Burke AE, Wang A, Pennell PB. Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy. Neurology. 2018;91(11):e1031-e1039.
23. Fountain NB, Van Ness PC, Bennett A, et al. Quality improvement in neurology: epilepsy update quality measurement set. Neurology. 2015;84(14):1483-1487.
24. Trussell JAA. Contraceptive efficacy. In: Hatcher NA, Trussell J. (Eds). Contraceptive Technology. 2018, Ayer Company Publishers, Inc.: New York, NY.
25. Herzog AG, Mandle HB, MacEachern DB. Prevalence of highly effective contraception use by women with epilepsy. Neurology. 2019;92(24):e2815-e2821.
26. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-104.
27. Bhakta J, Bainbridge J, Borgelt L. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Epilepsy Behav. 2015;52(Pt A):212-217.
28. Espinera AR, Gavvala J, Bellinski I, et al. Counseling by epileptologists affects contraceptive choices of women with epilepsy. Epilepsy Behav. 2016;65:1-6.
29. Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia. 2008;49(S9):43-55.
30. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peña-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;(10):CD007950.
31. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1247-1255.
32. Ban L, Fleming KM, Doyle P, et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLoS One. 2015;10(7):e0131130.
33. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029-1034.
34. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2009;80(5):506-511.
35. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609-617.
36. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244-252.
37. Bjørk M, Riedel B, Spigset O, et al. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero. JAMA Neurol. 2018;75(2):160-168.
38. Husebye ESN, Gilhus NE, Riedel B, Spigset O, Daltveit AK, Bjørk MH. Verbal abilities in children of mothers with epilepsy: association to maternal folate status. Neurology. 2018;91(9):e811-e821.
39. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1-13.
40. Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699.
41. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538.
42. Holmes LB, Hernandez-Diaz S, Quinn M, Guillen JF, Weidman-Dahl F, Coleman C. North American AED Pregnancy Registry. Available at http://www.aedpregnancyregistry.org/wp-content/uploads/The-NA-AED-Pregnancy-Registry-AES-2018.pdf. Accessed September 19, 2019.
43. Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696-1703.
44. Christensen J, Pedersen L, Sun Y, Dreier JW, Brikell I, Dalsgaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Netw Open. 2019;2(1):e186606.
45. United States Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-valproate-anti-seizure-products-contraindicated-migraine-prevention. Published February 26, 2016. Accessed August 30, 2019.
46. European Medicines Agency. PRAC recommends new measures to avoid valproate exposure in pregnancy. https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-valproate-exposure-pregnancy. Published September 2, 2018. Accessed August 30, 2019.
47. Tomson T, Battino D, Bonizzoni E, et al. Declining malformation rates with changed antiepileptic drug prescribing: An observational study. Neurology. 2019;93(9):e831-e840.
48. Karlsson Lind L, Komen J, Wettermark B, von Euler M, Tomson T. Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions. Epilepsia Open. 2018;3(3):357-363.
49. Puteikis K, Medžiaušaité I, Mameniškiené R. Valproate utilisation trends among girls and women from 2013 to 2018. Seizure. 2019;70:77-81.
50. George IC, Bartolini L, Ney J, Singhal D. Differences in treatment of epilepsy in pregnancy: a worldwide survey. Neurol Clin Pract. 2019;9(3):201-207.
51. Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013;54(9):1621-1627.
52. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989-1008.
53. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure. 2008;17(2):160-165.
54. Reimers A, Brodtkorb E, Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother. 2012. 12(6):707-717.
55. Polepally AR, Pennell PB, Brundage RC, et al. Model-based lamotrigine clearance changes during pregnancy. Ann Clin Transl Neurol. 2014;1(2):99-106.
56. Pirie DA, Al Wattar BH, Pirie AM, et al. Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;172:26-31.
57. Thangaratinam S, Marlin N, Newton S, et al. Antiepileptic drug monitoring in pregnancy (EMPIRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018;22(23):1-152.
58. Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia. 2014;55(7):e72-e74.
59. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75(11):1575-1583.
60. Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29(1):13-18.
61. Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-e841.
62. Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013;70(11):1367-1374.
63. Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168(8):729-736.
64. Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. Seizure. 2015;28:57-65.
65. US National Library of Medicine. TOXNET: toxicology data network. Drugs and lactation database (LactMed). https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm. Accessed August 31, 2019.
66. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40(2):205-210.
67. Harden CL. Menopause and bone density issues for women with epilepsy. Neurology. 2003;1;61(6 Suppl 2):S16-S22.
68. Sveinsson O, Tomson T. Epilepsy and menopause: potential implications for pharmacotherapy. Drugs Aging. 2014;31(9):671-675.
69. Hakami T, O’Brien TJ, Petty SJ, et al. Monotherapy with levetiracetam versus older AEDs: a randomized comparative trial of effects on bone health. Calcif Tissue Int. 2016;98(6):556-565.
70. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86(5):1466-1474.
71. Fernandez H, Mohammed HT, Patel T. Vitamin D supplementation for bone health in adults with epilepsy: a systematic review. Epilepsia. 2018;59(4):885-896.
MJC and JDK report no disclosures.